Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

xuna30 enrolled

Overview

Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation 1. Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF) 2. With at least two month Ruxolitinib treatment prior to transplantation 3. DAC+BF as myeloablative conditioning regimen 4. CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of 7.5mg/KG for mismatch donor 5. received Rux at +6d in ASCT and continued to +60d

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Time of Hematopoietic Reconstruction

Interventions

comprehensive treatment regimenOTHER

1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF) 2. With at least two month Ruxolitinib treatment prior to transplantation 3. DAC+BF as myeloablative conditioning regimen 4. received Rux at +5d in ASCT and continued to +60d

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 18-60 years old, gender is not limited; 2. Diagnosis MF(includ Post-ET,Post-PV,PMF) according to 2016 WHO 3. With at least two month Ruxolitinib treatment before transplantation 4. Informed consent of the patient or his legal representative Exclusion Criteria: 1. HCT-CI score≥2 2. Woman who is pregnant or nursing 3. MPN Patients who have received allogeneic hematopoietic stem cell transplantation

Locations (1)

NanfangH

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

Time of neutrophils reconstruction

Neutrophils count≧0.5G/L without G-CSF

Time frame: 1 year

Secondary Outcomes

The incidence rate of GVHD

The incidence rate of aGVHD and cGVHD

Time frame: 1 year

Central Contacts

na J xu

CONTACT

8618620698390 sprenaa@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.